Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults aged 65 years or older with HIV-1
2017-003428-61Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bictegravir, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: HIV-1 RNA less than 50 copies/mL at Week 24. Started Oct 2017; status: completed.
02
Drugs
bictegraviremtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-003428-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003428-61.